THE LEVEL OF SOME PRO- AND ANTI-INFLAMMATORY CYTOKINES IN MICE BEARING HIGHLY ANGIOGENIC LEWIS LUNG CARCINOMA AFTER APPLICATION OF CANCER VACCINES
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-22-3-2020-g.9043Keywords:
antitumor vaccines, Lewis lung carcinoma LLC/R9, tumor-associated anemia, ІЛ-10, ІЛ-1β, ІЛ-4, ІФН-γAbstract
Aim: To investigate the level of some pro- and anti-inflammatory cytokines in mice bearing highly angiogenic variants of Lewis lung carcinoma after the application of anticancer vaccines based on cell antigens of highly angiogenic (LLC/R9) or low-angiogenic (LLC) variants of the carcinoma. Object and methods: The study was performed on male C57/Bl mice bearing LLC/R9. As an adjuvant, a protein-containing metabolite of B. subtilis with m.m. of 70 kDa was used in cancer vaccine production (based on LLC or LLC/R9 cells). The vaccination schedule consisted of 4 subcutaneous injections that were started on day 12 after the LLC/R9 transplantation. Intact mice and unvaccinated mice bearing LLC/R9 were used as the control. On day 33 of tumor growth, the level of tumor necrosis factor alpha (TNF-α), interferon gamma (IFN-γ), interleukin (IL) -1, -4, -10 were determined in blood serum (BS) and splenocytes supernatants. Results: IL-10 and IFN-γ play an important role in the development of tumor-associated anemia in mice bearing LLC/R9. The application of the vaccine based on LLC cells prevented the accumulation of IFN-γ in the BS at the late stages of tumor growth; this most likely underlies the possibility to gain antitumor protection, sufficient to reach antimetastatic effect. Nevertheless, this vaccine did not prevent the formation of an immunosuppressive state (increased ability of splenocytes to produce IL-10 with a simultaneous decrease in the production of IL-1β). The vaccine based on LLC/R9 cells, at the late stages of tumor growth, did not affect the BS level of IFN-γ and increased the level of IL-4 and IL-1β, which most probably caused the development of more severe anemia in this group. Moreover, this vaccine did not affect the functional state of splenocytes: a decrease in IFN-γ production was noted. Conclusion: the obtained results confirm the humoral (in particular, because of cytokines IL-10, IFN-γ and IL-1β level) mechanism of LLC/R9-assosiated anemia development; this can set the ground for the development of indications for autologous vaccines application according to paraneoplastic syndromes manifestations.
References
Bilynsky BT, Dzhus MB, Litvinyak RI. The conceptual and clinical problems of paraneoplastic syndrome in oncology and internal medicine. Exp Oncol 2015; 37: 82–8.
Blyakhman I, Chakravarthy K. Updated review and treatment recommendations on paraneoplastic neurologic syndromes and chronic pain. Pain Physician 2019: 22: 433–45.
Henry K. Paraneoplastic syndromes: Definitions, classification, pathophysiology and principles of treatment. Sem Diagnostic Pathol 2019; 36 (4): 204–10.
Boyiadzis M, Lieberman FS, Geskin LJ, et al. Paraneoplastic syndromes. In: Cancer: principles and practice of oncology. 8th ed. DeVita VT, Lawrence TS, Rosenberg SA (eds). New York: Lippincott, Williams & Wilkins, 2008: 2343–62.
Schwartz RN. Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols. Am J Health Syst Pharm 2007; 64: S5–S13.
Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc 2010; 85 (9): 838–54.
Debeljak N, Solár P, Sytkowski AJ. Erythropoietin and cancer: the unintended consequences of anemia correction. Front Immunol 2014; 5: Article 563: 1–14.
Peskovskaya OM, Solyanyk GI, Fedorchuk, et al. The method of obtaining a modified variant of Lewis lung cancer. Pat. №48525 Ukraine, MPK G 01 N 33/15. №u2009 08956; stat. 28.08.2009; publish. 25.03.2010, Bull. № 6 (in Ukrainian)
Pyaskovskaya ON, Dasyukevich OI, Kolesnik DL, et al. Changes in VEGF level and tumor growth characteristics during Lewis lung carcinoma progression towards cis-DDP resistance. Exp Oncol 2007; 29 (3): 197–202.
Fedorchuk OG, Pyaskovskaya OM, Skivka LM, et al. Paraneoplastic syndrome in mice bearing high-angiogenic variant of Lewis lung carcinoma: Relations with tumor derived VEGF. Cytokine 2012; 57 (1): 81–8.
Pyaskovskaya OM, Gorbyk GV, Yakshibaeva YUR, et al. Correction of tumor-associated anemia with grape polyphenols. Farmakol ta likarsʹka toksykol 2014: (1 (37)): 91–8.
Sarnatskaya VV, Nikolaev VG, Yushko LA, et al. Effect of enterosorption on paraneoplastic symptom manifestation in mice with highly angiogenic variant of Lewis lung carcinoma. Exp Oncol 2015; 37 (4): 255–61.
Karaman ОМ, Fedosova NІ, Voyeykova ІМ, et al. Manifestations of tumorassociated anemia in mice with Lewis lung carcinoma at the background of use of cancer vaccines. Onkologiya 2016; 18 (4): 262–8 (in Ukrainian).
Lavrova VS, Chernova YeN, Karpova GV, et al. Disregulating processes in the blood system during cancer. Bull Sib Med 2006; (2): 75–84 (in Russian).
Bron D, Meuleman N, Mascaux С. Biological basis of anemia. Semin Oncol 2001; 28 (2, Suppl 8): 1–16.
Kozhemyakin YuM, Khromov OS, Boldyreva NE, et al. Scientific and practical recommendations for keeping laboratory animals and working with them. K: Interservis, 2017. 182 p. (in Ukrainian).
Council Directive 2010/63/EU of 22 september 2010 on the protection of animals used for scientific purposes. Official J Eur Commun 2010; 276: 33–79.
Klaus J. Lymphocytes. Methods. M: Mir, 1990. 395 p. (in Russian).
Kovbasyuk SA, Yudin VM, Kravchenko SP. Immunomodulatory effect of cyclophosphamide with various schemes of its administration to mice. Cytologia 1985; (3): 316–21 (in Russian).
Sidenko AV, Vishnyakov VV, Isaev SM. The theory of statistics. Manual. М: MAKS-Press, 2011. 343 p. (in Russian).
Tilg H, Ulmer H, Kaser A, Weiss G. Role of IL-10 for induction of anemia during inflammation. J Immunol 2002; 169 (4): 2204–9.
Mojic M, Takeda K, Hayakawa Y. The dark side of IFN-γ: its role in promoting cancer immunoevasion. Int J Mol Sci 2017; 19 (1): 89.
Lee HL, Jang JW, Lee SW et al. Inflammatory cytokines and change of Th1/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization. Sci Rep 2019; 9: 3260.
